| Rank |
Status |
Study |
| 1 |
Unknown †
|
Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding
| Condition: |
Nonvariceal Upper Gastrointestinal Bleeding |
| Interventions: |
Drug: Intravenous Omeprazole; Drug: Oral Rabeprazole |
| Outcome Measure: |
This study aims to compare the effect of three-day oral rabeprazole and iv omeprazole on bleeding control in patients with mild to moderate non-variceal UGIB. |
|
| 2 |
Unknown †
|
Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets
| Conditions: |
Gastric Ulcer; Duodenal Ulcer |
| Intervention: |
Drug: rabeprazole plus aspirin versus rabeprazole plus clopidogrel |
| Outcome Measures: |
The primary end point is treatment success (ulcer healing rate).; The secondary end point is incidence of ulcer bleeding within 12 weeks. |
|
| 3 |
Recruiting
|
A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors
| Condition: |
Cancer |
| Interventions: |
Drug: Dabrafenib 150 mg twice a day (BID); Drug: Rabeprazole 40 mg once daily (OD); Drug: Rifampin 600 mg OD |
| Outcome Measures: |
PK assessment (Cmax) of Dabrafenib with and without Rabeprazole or Rifampin; PK assessment (tmax) of Dabrafenib with and without Rabeprazole or Rifampin; PK assessment (AUC[0-tau]) of Dabrafenib with and without Rabeprazole or Rifampin; PK assessment of Dabrafenib co administered with rabeprazole or rifampin; PK assessment (AUC[0-tau]) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib; PK assessment (Cmax and Ctau,) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib; PK assessment (tmax) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib; Ratio of metabolite to Dabrafenib; Safety and tolerability assessment to measure vital signs; Safety and tolerability assessment for 12-lead ECG; Safety and tolerability assessment for laboratory tests; Safety and tolerability assessment of dabrafenib in combination with rabeprazole or rifampin; Concentrations of Rabeprazole in the presence of Dabrafenib; Concentrations of Rifampin in the presence of Dabrafenib |
|
| 4 |
Unknown †
|
Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections
| Condition: |
Helicobacter Pylori Infection |
| Interventions: |
Drug: RA5-RACM7; Drug: RA3-RACM7; Drug: RA7-RACM7 |
| Outcome Measure: |
Eradication rate |
|
| 5 |
Recruiting
|
Concomitant Therapy of H. Pylori
| Condition: |
Gastritis, Gastric Ulcer, and Duodenal Ulcer |
| Intervention: |
Drug: amoxicillin, clarithromycin, metronidazole, rabeprazole |
| Outcome Measure: |
Evaluation of the efficacy of concomitant therapy for eradication of Helicobacter pylori |
|
| 6 |
Recruiting
|
Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food
| Condition: |
Healthy |
| Interventions: |
Drug: palbociclib commercial free base; Drug: famotidine; Drug: rabeprazole; Drug: antacid |
| Outcome Measures: |
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]; Maximum Observed Plasma Concentration (Cmax); Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast); Apparent Oral Clearance (CL/F); Time to Reach Maximum Observed Plasma Concentration (Tmax); Apparent Volume of Distribution (Vz/F); Plasma Decay Half-Life (t1/2) |
|
| 7 |
Recruiting
|
H2RA VS PPI for the Prevention of Ulcer Bleeding Associated With Low-dose Aspirin in Patients With Very High Ulcer Risk
| Condition: |
Peptic Ulcer Bleeding |
| Interventions: |
Drug: Rabeprazole; Drug: Famotidine |
| Outcome Measures: |
Recurrent ulcer bleeding; Lower GI bleeding; serious cardiothrombotic events |
|
| 8 |
Recruiting
|
Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
| Condition: |
Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive |
| Intervention: |
Drug: Rabeprazole Sodium |
| Outcome Measures: |
Response rate of gastric low-grade MALT lymphoma by eradication of Helicobacter pylori; Transition rate to secondary therapy for eradication of Helicobacter pylori |
|
| 9 |
Unknown †
|
Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy
| Condition: |
Bacterial Infection Due to Helicobacter Pylori (H. Pylori) |
| Interventions: |
Drug: 10RAC+acetylcystein; Drug: 10RAC+metronidazole |
| Outcome Measures: |
Re-eradication rate; Influence of Participant's CYP2C19 genotype on re-eradication rate |
|
| 10 |
Unknown †
|
Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection
| Conditions: |
Helicobacter Infections; Gastritis; Gastric Ulcer; Duodenal Ulcer |
| Intervention: |
Drug: rabeprazole, amoxicillin, clarithromycin, metronidazole |
| Outcome Measures: |
Which treatment yields the higher re-eradication rate of H. pylori infection; Side effects |
|
| 11 |
Recruiting
|
The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD
| Condition: |
Reflux Esophagitis |
| Intervention: |
Drug: Newrabell® Tablet 10mg |
| Outcome Measures: |
Time to onset of first 1Day Heartburn free, Days; Time to onset of first 2Days Heartburn free, Days; 1Day Heartburn free days, %; Time in Daytime of first Heartburn free, Days; Time in Nighttime of first Heartburn free, Days; Weekly Heartburn Improvement Rate, %; Average Daytime and Nighttime Heartburn Score Change at W4; Average Daytime and Nighttime Heartburn Score Change at W8 |
|
| 12 |
Unknown †
|
A Study of the Use of High-dose Proton Pump Inhibitor for the Treatment of Gastro-oesophageal Reflux Related Non-cardiac Chest Pain - a Randomized Double-blind Placebo-controlled Study
| Condition: |
Chest Pain |
| Intervention: |
Drug: Rabeprazole 20mg twice daily |
| Outcome Measures: |
Symptoms assessment, quality of life.; Compliance; Adverse effects |
|
| 13 |
Unknown †
|
Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment
| Condition: |
Gastroesophageal Reflux Disease (GERD) |
| Interventions: |
Procedure: Transoral Incisionless Fundoplication; Drug: Proton Pump Inhibitors; active control |
| Outcome Measures: |
GERD symptoms; PPI usage; Lower esophageal acid exposure; Healed reflux esophagitis; Rate of adverse events |
|
| 14 |
Recruiting
|
The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD
| Condition: |
Gastroesophageal Reflux Disease |
| Intervention: |
Drug: Proton pump inhibitor (rabeprazole) |
| Outcome Measure: |
Symptom responders after PPI trials |
|
| 15 |
Unknown †
|
Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping ™ Assay
| Condition: |
30 Healthy People |
| Intervention: |
Drug: Clopidogrel and proton pump inhibitors |
| Outcome Measure: |
Comparison of the antiplatelet drug response apparently shown in TEG & Platelet mapping assay |
|
| 16 |
Recruiting
|
The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients
| Conditions: |
Non-erosive Reflux Disease; Barrett's Esophagus |
| Interventions: |
Device: Ryodoraku; Device: ANSWatch; Device: UGI endoscopy; Other: GerdQ; Drug: PPI |
| Outcome Measures: |
gastroesophageal reflux disease questionnaire; Upper gastrointestinal endoscopy |
|
| 17 |
Recruiting
|
Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy
| Condition: |
Helicobacter Pylori Infection |
| Interventions: |
Drug: high dose dual therapy; Drug: concomitant therapy |
| Outcome Measures: |
to compare the efficacy of 10-day concomitant regimen versus high dose dual therapy used as atni-Helicobacter pylori rescue therapy; to compare the adverse effects and patient adherence of 10-day concomitant regimen versus high dose dual therapy used as atni-Helicobacter pylori rescue therapy |
|
| 18 |
Unknown †
|
Symptom Assessment for GERD Patients Receiving H. Pylori Eradication
| Condition: |
Gastroesophageal Reflux Disease |
| Intervention: |
|
| Outcome Measure: |
The incidence and severity of acid-related symptoms with GerdQ |
|
